血管内治疗中血管痉挛:相关因素、预后影响及动脉内尼莫地平的作用
血管痉挛与90天改良Rankin量表预后更差及死亡率升高相关,动脉内尼莫地平可能减少早期神经功能恶化。
要点
- 血管痉挛与90天mRS预后更差(aOR 1.25)及死亡率升高(36% vs 29.7%,aOR 1.35)相关。
- 动脉内尼莫地平与早期神经功能恶化减少相关(aOR 0.54)。
- 年轻、吸烟、M2闭塞、支架取栓及多次再通尝试与血管痉挛相关。
核心结论
- 血管内治疗中血管痉挛与更差预后和死亡率增加相关,应视为严重操作并发症。
- 动脉内尼莫地平可能是合理治疗,或可减轻神经功能恶化且无潜在伤害信号。
研究设计与样本
- 研究采用德国卒中登记-血管内治疗的前瞻性、观察性、多中心注册数据。
- 比较有无血管痉挛患者,并在血管痉挛患者中比较使用与未使用动脉内尼莫地平的预后。
主要发现
- 578例(3.2%)报告血管痉挛,其中300例(58.4%)接受动脉内尼莫地平。
- 血管痉挛与90天mRS预后更差相关(aOR 1.25,95%CI 1.02-1.53)。
- 血管痉挛与死亡率升高相关(36% vs 29.7%;aOR 1.35,95%CI 1.05-1.75)。
- 动脉内尼莫地平与早期神经功能恶化减少相关(aOR 0.54,95%CI 0.31-0.91)。
- 与血管痉挛相关的变量包括年轻年龄、主动吸烟、M2闭塞、一线支架取栓及多次再通尝试。
临床怎么用
- 血管内治疗中应警惕血管痉挛,尤其年轻、吸烟、M2闭塞、支架取栓及多次再通尝试患者。
- 对发生血管痉挛者可考虑动脉内尼莫地平以减轻早期神经功能恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vasospasm occurs in up to 20% of patients with acute ischemic stroke undergoing endovascular treatment, but its clinical impact remains controversial. Intraarterial nimodipine is administered occasionally to treat vasospasm, though its efficacy is uncertain. We aimed to identify factors associated with vasospasm, delineate the impact on clinical outcomes, and assess the effects of intraarterial nimodipine use. METHODS: We used data from the German Stroke Registry-Endovascular Treatment, an investigator-initiated, prospective, observational, multicenter registry of patients with acute stroke who underwent endovascular treatment at 25 centers between June 2015 and December 2023. Patients with and without vasospasm were analyzed, and among those with vasospasm, we compared outcomes based on intraarterial nimodipine use. The primary outcome was the distribution of modified Rankin Scale scores at 90 days. Secondary outcomes included 90-day mortality, early neurological deterioration, symptomatic intracranial hemorrhage at 24 hours, and successful recanalization (modified Thrombolysis in Cerebral Infarction Score of 2b to 3). Analyses used Inverse Probability of Treatment Weighting adjusted logistic regression; variable selection was performed using Least Absolute Shrinkage and Selection Operator regression. RESULTS: Seventeen thousand nine hundred eighty-five patients (mean age 73.6 years; 51.2% female) were included in the analysis. Of these, 578 (3.2%) had vasospasm reported, and 300 (58.4%) of those received intraarterial nimodipine. Vasospasm was associated with a shift towards worse modified Rankin Scale outcome (adjusted odds ratio, 1.25 [95% CI, 1.02-1.53]) and higher mortality (36% versus 29.7%; adjusted odds ratio, 1.35 [95% CI, 1.05-1.75]). Intraarterial nimodipine was associated with reduced rates of early neurological deterioration (adjusted odds ratio, 0.54 [95% CI, 0.31-0.91]). Variables associated with vasospasm included younger age, active smoking, M2 occlusion, first-line stent retriever thrombectomy, and multiple recanalization attempts. CONCLUSIONS: Vasospasm during endovascular treatment is associated with worse outcomes and increased mortality, and should be regarded as a serious procedural complication. Younger patients who are active smokers, presenting with distal occlusions, and require multiple recanalization attempts are at higher risk. Intraarterial nimodipine appears to be a sensible treatment as it may mitigate neurological deterioration without signals of potential harm.
引用
- Wischmann J, Rattenberger A, Nolte CH, et al. Vasospasm During Endovascular Treatment of Ischemic Stroke: Associated Factors, Impact on Outcomes, and the Effect of Intraarterial Nimodipine. Stroke. 2025. PMID: 41332394. doi:10.1161/STROKEAHA.125.053600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。